Picture a buyer who is not short of money but is bound by a ratio, and who has agreed to expand the shop in the same month. The buyer registers half the house in its own name. A long-standing associate buys the other half. The two sign an agreement: when conditions they have set are met, the associate may sell its half back, and the buyer may buy it first. Only the two of them know the conditions. The register says half; the whole street knows whose house it is.
In finance this is a co-investment with a put option (the holder’s right to sell at agreed terms) and a call option (the counterparty’s right to buy). Hanwha Life, the Korean life insurer, used it to acquire Acuon Capital — a specialty lender that owns 100% of Acuon Savings Bank — from its selling sponsor, EQT, taking only the 50.54% it needed for control and leaving the balance with Centroid, a private equity manager in which Hanwha Life itself holds a 15% stake. The Hanwha Life Acuon Capital acquisition is usually described as the last missing piece of a bank-less financial group. That description is true and explains nothing.
It does not explain why a lender earning a 1.7% interest margin is worth roughly KRW 870 billion, and it does not explain why the buyer paid for only half. This article follows both questions through the numbers. The desk’s read: the deal’s centre of gravity is not the KRW 440 billion on the board resolution but a clause nobody outside the agreement can read — the one that determines when, at what price, and on whose election the other half comes home.
The Deal
The terms below are drawn from Hanwha Life’s board resolution of September 30 and subsequent disclosures, as reported in Korean media. Where the desk estimates, it says so.
- Target: Acuon Capital, a Korean specialty lender with roughly KRW 3 trillion of loan assets on a separate basis, which holds 100% of Acuon Savings Bank (total assets about KRW 5.1 trillion). Both companies transfer in one transaction.
- Buyer: Hanwha Life. Its board approved acquiring 50.54% of Acuon Capital for KRW 440 billion (approx. USD 314 million at KRW 1,400/USD, house reference rate, October 2026). Grossed up, that implies about KRW 870 billion (approx. USD 621 million) for 100%, consistent with the reported total deal value.
- Co-investor: Centroid takes the remaining stake of roughly 49%, worth about KRW 430 billion, reportedly through a project fund combined with acquisition financing. Hanwha Life acquired a 15% stake in Centroid earlier this year, making it the manager’s second-largest shareholder.
- Seller: EQT, which reportedly bought roughly 90% of Acuon in 2019 for about KRW 700 billion — around KRW 770 billion on a 100% basis.
- Shareholder agreement (disclosed in outline only): Centroid’s fund may sell its stake to Hanwha Life when conditions set in the agreement are met; Hanwha Life holds a right to buy that stake under certain conditions and a right of first refusal (ROFR — the right to match any third-party offer before the stake can be sold). The conditions and the pricing mechanism are not disclosed.
- Same-day context: Hanwha Life’s board also approved a KRW 250 billion contribution to Hanwha Investment & Securities’ rights issue — KRW 690 billion of commitments in a single day.
Structure Breakdown
Start inside the company. Acuon Capital’s net interest income for the first half of this year was KRW 25.8 billion on a separate basis, which annualises to roughly 1.7% of loan assets. Its cost ratio is a lean 1.27%, but once credit costs are deducted, lending alone leaves little margin.
Last year’s separate net income was KRW 45.5 billion, and the gap is filled by an item the lending margin does not explain: income from alternative assets of KRW 78.2 billion, up 83.6% year on year and larger than operating profit of KRW 61.1 billion. That figure cannot simply be labelled one-off — it may contain recurring interest and dividends, and it is not net of the funding cost of carrying those positions. What is certain is that investment assets stood at KRW 933.5 billion at the end of June, about a fifth of separate total assets, so this company’s earnings depend on investment performance as much as on lending.
The subsidiary is not earning at present. Acuon Savings Bank reported first-half net income of KRW 1.3 billion on about KRW 5.1 trillion of assets, against KRW 10.2 billion in the same period two years earlier. Total loans fell 11.3% in a year to KRW 4,369.8 billion as the bank cut real estate and personal lending; its NPL ratio (non-performing loans as a share of total loans) improved from 6.43% to 6.25% and delinquency from 5.09% to 4.84%. Asset quality is turning before profit has.
Thin margin, investment-dependent earnings, a subsidiary waiting for recovery — so where is the force that lifts the price? Much of it sits outside the company, with the new owner. Acuon Capital’s funding cost last year was 5.05% on KRW 2.55 trillion of outstanding bonds, with an A rating: the terms of a sponsor-owned independent lender. Hanwha Life is among Korea’s top-rated insurers, and Korea Investors Service placed Acuon Capital on review for upgrade immediately after the preferred bidder was named, citing the prospect of group support in a stress event.
From here the desk is assuming. If the KRW 2.55 trillion rolls over at 0.5 percentage points lower as each maturity refinances, the saving once fully rolled is roughly KRW 12.8 billion pre-tax a year — more than a quarter of last year’s separate net income. The size and speed depend on how far the rating moves and how maturities fall, but the direction is unambiguous: earnings can rise without a single change to operations. The first value driver in this deal is the transplant of credit. The second, a recovery in savings bank earnings, remains an expectation.
On price, the desk could not confirm consolidated equity. Back-solving from disclosed ratios puts it somewhere around KRW 900 billion, which would make the entry roughly 1x book value — about 13x last year’s consolidated net income of KRW 65.6 billion, and about 9.5x annualised first-half earnings. On ordinary assumptions, 1x book is justified only if return on equity holds near 10%. Last year fell short; the first-half trend would need to persist. This reads as a price paid on the premise of recovery rather than a cheap purchase — with low confidence, because the base figures are estimates. In fairness, the seller’s 2019 entry of about KRW 770 billion grossed up, against KRW 870 billion seven years later, is not an overheated mark, even before the dividends and add-on purchases the comparison ignores.
Then why half? Not for want of cash. KRW 440 billion is 2.65% of Hanwha Life’s consolidated equity, and the rating agency judged the financial burden limited. The constraint is a ratio: Hanwha Life’s basic-capital K-ICS ratio (the Korean insurance solvency measure, counted on core capital only) stood at 56.8% at end-June against a 50% requirement that applies from next year, with transitional relief running to 2035. Headroom is 6.8 percentage points, and the same board committed KRW 250 billion to the securities arm’s rights issue. The company said as much itself: it bought only the stake control requires in order to reduce the financial burden.
The Governing Logic
An architect designs a structure not to make money but to avoid losing it. Take the financial investor’s seat and count. The figures that follow are estimates layered on public results; the actual share and rate of acquisition financing, and the actual put terms, are not disclosed.
Everything about this structure is weighted toward protecting principal rather than selling, because of where the stake sits: 49% without control, in an unlisted financial company, beneath a majority holder with a right of first refusal. A sale to a third party is close to foreclosed. In that seat the market does not price the stake; the contract does.
Base case: consolidated net income averages KRW 95 billion over five years, the company pays about KRW 12.5 billion a year in dividends, and the stake exits at 1x book in year five. KRW 430 billion in returns roughly KRW 650 billion of stock and about KRW 31 billion of cumulative dividends — about 1.58x unlevered, a 9–10% annual return. Decompose it and the character shows: about 82% is earnings retained inside the company, about 12% is dividends, and barely 6% comes from multiple. Buying at around book and selling at book is not a buy-low-sell-high trade. It is five years of waiting for the company to earn and accumulate.
Now add debt. Centroid is reported to be using a project fund alongside acquisition financing. Assume half the ticket at 6.5%: interest is about KRW 14 billion a year. Dividends attributable to the stake on the same assumptions are about KRW 6.2 billion — smaller than intuition suggests, because dividends are paid out of Acuon Capital’s separate earnings, not consolidated earnings. The gap is roughly KRW 7.8 billion a year, about KRW 39 billion over five years. Settle it in a lump at exit and the base case still returns about 1.83x on equity, around 13% a year. The problem is the five years in between: interest leaves annually and the inflow does not cover it, and the party that sets the dividend is not the financial investor but the majority holder.
This is where the two shareholders’ interests part. Acuon Capital has set a target of KRW 5 trillion in separate assets. A lender that wants to grow its book must retain capital, which means conserving dividends — a natural choice for Hanwha Life, which wants the scale of a full financial group. A fund with a maturity and an interest bill needs the dividends. The market has already noted that reconciling payout and reinvestment after closing will matter.
Downside case: net income averages KRW 60 billion and the exit multiple falls to 0.7x book. Unlevered, the stake ends near par. With half the ticket borrowed, the equity recovers something in the 0.6x range. Minority stakes in financial companies marking below book are not rare; this is not an extreme assumption.
Hence the put. In this seat it is not an appendix to the thesis; it is the thesis. What kind of instrument it is depends on terms the desk cannot see. If the put price is fixed at principal plus a return, the stake becomes something close to a bond drawn on Hanwha Life’s credit. If the price is fair value at exercise, there is a buyer but the downside stays open. Whether the trigger is the passage of time or a defined event changes the answer again. The disclosure says only that the right becomes exercisable when the agreement’s conditions are met.
Downside Protection
Now Hanwha Life’s chair. It too built the structure to avoid losing — not cash, but a capital ratio. Taking only the majority halved the day-one outlay. The call option and right of first refusal block the remaining stake from passing to an unwelcome third party and let Hanwha Life collect it directly when headroom allows. The right to choose the moment is not held by one side; it is split.
The structure is not free. The financial investor’s required return is the price Hanwha Life pays for time. If that return is close to what Hanwha Life would pay to issue its own capital securities, this is not an expensive deal — it is financing in a different form. The difference is not the rate; it is the maturity. A bond has a date. This agreement matures on the day its conditions are satisfied, and that day is unknown to anyone outside it. Per past reports, Hanwha’s group has walked this path before: it entered Korea Life with consortium partners and later bought more shares when a partner exercised its put. Whether the same ending is intended here is unknowable; the shape is familiar.
The most delicate point is the loop. Hanwha Life is Centroid’s second-largest shareholder. A fund run by a manager Hanwha Life part-owns buys the other half, and that fund may sell it back to Hanwha Life. The investor’s downside rests on Hanwha Life’s capacity to perform; Hanwha Life’s ratio management rests on the investor’s willingness to hold for time. Each is the other’s safety device — efficient in fair weather, and in foul weather both devices are tested at once.
What Must Be True
Three propositions carry the read. Each is stated with what has been confirmed, what has not, and what would falsify it.
1. The earnings that justify the price must be repeatable. Confirmed: alternative asset income jumped 83.6% to KRW 78.2 billion in the year before the sale. Not confirmed: whether that recurs or reflects realisations bunched into one year. If the former, it is the company’s stamina; if the latter, the earnings behind the entry price are inflated. Falsifier: a deal-by-deal breakdown of investment income showing concentration in exit timing. A second indicator points the same way. In the first half, Acuon Capital’s delinquency fell from 2.82% to 2.68% while its NPL ratio rose from 3.31% to 3.76%, which the company attributes to reclassifying precautionary loans and slower recoveries. Conservative pre-sale classification would be a good sign; problem assets surfacing before they reach delinquency would be a bad one. The rating agency has flagged a real estate book skewed toward non-residential and mezzanine or subordinated positions.
2. The savings bank must not call on its parent. Its capital ratio of 12.18% clears the 8% regulatory floor, but for a bank with a 6.25% NPL ratio it is not ample. If losses widen again, Acuon Capital would fund the shortfall — money that could otherwise have been paid as dividends to the shareholders, including the levered one. Falsifier: a capital injection into Acuon Savings Bank within the first years after closing.
3. The shock that triggers the put must not be the shock that pins the buyer. Taken separately, the three risks above are manageable. The worry is that all three answer to one variable. If rates rise again and non-residential property turns, mezzanine loan losses, investment marks and savings bank delinquencies can move together; a book that looked divided into lending, investing and retail reacts to a single impulse. The sequence then runs: Acuon’s earnings fall, dividends are cut to support the bank, the fund’s interest burden accumulates, and — if the agreement allows — the put is exercised at exactly the moment Hanwha Life’s own ratio is compressed by the same shock. The time to buy coincides with the worst time to buy. Korea has precedent for a life insurer and a financial investor disputing a put price for years; a prolonged dispute turns the stake into an unsellable asset.
In fairness: the whole transaction is a little over 5% of Hanwha Life’s equity, the rating agency sees the burden as limited, transitional relief runs to 2035, and nothing today suggests Hanwha Life cannot honour its commitments. But it is simultaneously pursuing the securities rights issue and the acquisition of another life insurer. Each promise is light; several sit on the one scale that is the capital ratio. Falsifier: Hanwha Life’s basic-capital ratio moving toward the 50% line while the put window is live.
One further variable is institutional. A fund managed by a firm 15%-owned by Hanwha Life holds 49%, with a right to sell to Hanwha Life attached. Whether the regulator treats that stake as an independent investor’s or as part of the Hanwha bloc is a judgement the desk cannot make. Savings bank major-shareholder reviews take time, and this is a period of heightened scrutiny of private equity owners. If the review runs long or arrives with conditions, part of the structure may have to be redrawn.
The Architect’s Takeaway
Strip the KRW 870 billion away and three designs remain that someone with little capital can use. If you were building your own deal room, these are the ones to transplant.
First, the credit transplant. Acuon Capital changed nothing about its business; the identity of its new owner alone put its rating on review for upgrade. A weaker name under a stronger one gets different terms for the same work, and that is not peculiar to finance. A third-year associate who walks in alone is judged on a CV; the same proposal inside a trusted institution’s or a respected senior’s project is judged on that name. So finding the name your work goes out under matters as much as polishing the work. Note the condition, though: Hanwha Life did not lend its rating for nothing — it filled a blank in its own group. The lender of the name must have a blank of its own to fill, and you must be able to say what it is before you ask.
Second, the separation of decision rights from money. Hanwha Life paid about half the price and holds control, and the control did not come from the agreement; it came from 50.54%. Buy only what control requires, and leave the rest open to other people’s money. Scaled down: a retiring owner’s business priced at KRW 500 million against KRW 200 million in hand. Trying to buy all of it means no deal. Buy the majority directly, let the owner keep a slice and stay on as adviser for a period, bring in one or two trusted co-investors for the balance — and write down on day one when and how the remaining shares will be settled. That is the Hanwha–Centroid arrangement at very small scale.
Third, design the exit before the entry. Centroid could buy 49% without control because a path out was written in. People do not join because the opportunity looks good; they join when they can see the way out. One distinction is non-negotiable here. The Hanwha–Centroid agreement is a shareholders’ agreement between professional investors, reviewed by counsel. An individual taking money from many people while promising to return principal is a different act and may be unlawful. The lesson is not to guarantee anyone’s money; it is to design terms that reduce the counterparty’s risk — an unconditional refund window for a paid course, stage gates with the right to stop in a collaboration, a fee-free initial period for suppliers on a platform, and for anything involving equity, a documented settlement mechanism drawn up with professionals.
The design carries three costs. A promise is worth exactly the capacity to keep it: if you promise refunds, the refund money must exist separately, just as the financial investor’s real diligence item here was not the clause but Hanwha Life’s ability to perform. Overlap: Hanwha Life signed two commitments in one day and is pursuing a third — and individuals do the same, promising refunds, interim settlements and fee waivers that are each light until a bad month makes everyone leave at once; test whether you survive the month in which every claim arrives together. Sequence: the 15% stake in Centroid came early in the year, the joint acquisition at the end of September. Whether the stake was the reason for the partnership is unconfirmed, but the order is fact — relationship first, transaction after — and for those with little capital the order matters more, because the small favours and small joint projects must already be in place when the large opportunity arrives.
The coldest lesson is the last one. Structure does not remove risk; it relocates where and when the risk lands. Hanwha Life halved today’s burden, and the other half remains as a contractual obligation. The moment you promise a refund or waive a fee, the counterparty’s risk has not vanished — it has moved to you. The person who carries that weight knowing it is an architect. The one who carries it unknowing is a guarantor.
Syndicate’s Note
House Verdict: TRACK. The structure’s weight sits in a clause the public cannot read, but the events that test the desk’s reading are scheduled and observable: the rating review outcome, the savings bank major-shareholder decision, and the first post-closing dividend set against a KRW 5 trillion asset target. Each will say whether the second half of this purchase is a co-investment or Hanwha Life’s deferred obligation wearing another party’s name.
Falsifier: if the regulator clears Centroid’s 49% as independent capital without conditions, the first dividend decisions show no tension between the asset target and the fund’s debt service, and the put is later confirmed as fair value at exercise, then the remainder was never Hanwha Life’s to come home to, and the read of financing in another form fails.
On classification: no entry in the Structure Pattern Library fits without distortion. The closest, The Synthetic Debt Mirage, describes a constrained seller dressing a held unit’s financing as minority equity; here the constraint sits with the buyer, the asset is an acquisition rather than a holding, and the options run both ways. The desk is queuing this mechanism as The Parked Remainder — the second half of a purchase parked with an allied investor under put, call and first refusal — pending a second independent case. The verdict classifies structural learning value; it is not an investment judgment.
FAQ
What is a put-call arrangement in a private equity co-investment?
A put gives the minority investor the right to sell its stake to the majority holder at agreed terms once defined conditions are met; a call gives the majority holder the right to buy it. Together with a right of first refusal, they fix who can end the partnership, when, and roughly on what terms — so the stake’s value is set by the contract rather than by a market that may not exist for it.
Why did Hanwha Life buy only 50.54% of Acuon Capital?
Not for lack of cash: the KRW 440 billion is 2.65% of its consolidated equity. The binding constraint is its basic-capital solvency ratio, 56.8% at end-June against a 50% requirement from next year, with a KRW 250 billion securities rights issue approved the same day. Buying only the controlling majority halved the day-one burden, and the company said so.
Does Hanwha Life’s ownership automatically raise Acuon Capital’s credit rating?
Not automatically, but Korea Investors Service placed Acuon Capital on review for upgrade immediately after Hanwha Life was named preferred bidder, citing potential group support. If an upgrade follows, Acuon’s KRW 2.55 trillion of bonds should refinance more cheaply over time; the desk’s illustrative estimate is about KRW 12.8 billion of annual pre-tax savings for a 0.5 percentage point reduction once fully rolled.
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation. Figures are based on public reports and may be estimates.
For more structural insights and deep-dive video breakdowns, visit Structure Syndicate on YouTube.